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Background: Since 2002, transapical aortic valve replacement has been developed as a clinical pathway for
transcatheter aortic valve implantation (TAVI). However the appropriate role of TA in the AS population versus TF
remains unclear. We performed a meta-analysis to assess if TF has any benefit in reduction of 30-day clinical
complications in AS.
Methods: We conducted a comprehensive search on pub-med and web of knowledge from 2002 through
September 2012 using following terms: aortic stenosis, aortic valve replacement, transcatheter aortic valve
implantation, TAVI, trans-artery, transfemoral, trans-apical. Studies in the original research or review articles were also
considered. Included studies must meet the preconditioned criterias. Two investigators independently browsed the
studies by title and abstract, finally making decision according to full-text. Disagreements were discussed in group.
Results: A total of 20 studies met inclusion criteria’s and were included in the analysis (including 4267 patients in
TF group, 2242 in TA group). No random clinical trial, one was a retrospective study, others were prospective trials. Our
meta-analysis found that TF had the low incidence of 30-day mortality compared with TA procedure (7.5% versus
11.3%). The incidence of stroke at≤ 30 days was relatively low (3.8% in TF versus 4.0% in TA). Although the incidence of
post-operative heart block was high (8.5% versus 7.5%), but no differences were indicated [1.06,95% CI(0.85,1.33)].
Conclusions: The result of our meta-analysis suggested that TF may have a low risk for 30-day mortality against TA
procedure. No difference was found in the incidence of post-operative stroke and heart block.
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Aortic valve disease is the most common acquired valvular
disease in developed and developing countries. Surgical
aortic valve replacement is the gold standard treatment for
patients with aortic stenosis. However, patients in high risk
with severe, symptomatic aortic stenosis arenot candidates
for surgical AVR. Since encouraging early results from
various centers, TAVI is increasingly seen and accepted as
an alternative procedure in high-risk patients [1-3].* Correspondence: dr_dongaiqiang@sina.com
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reproduction in any medium, provided the orThe TF approach was used in 66% of procedures, but in
case of small size and atheromatosis of the iliac arteries, this
approach is not suitable. The transapical approach is usu-
ally applied for patients with small, calcified,iliac arteries.
But the choice of the optimal access route is multifactorial.
Patients with inadequate iliac access are usually considered
asa high risk associated with bleeding, false aneurysm, or
orther vascular complications, which critically influencing
the outcome of the patient.
Currently, no randomized studies have been published
on the comparison of the TF versus the TA approach. In
our work, we aimed to compare 30-day complications
in patients with TF against a group of TA.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of included studies
Study Number of
patients TAVI
Logistic EuroSCORE STS SCORE 30-day outccomes
(%)* (%)* Mortality Stroke Vascular
complication
Heart block
TF TA Total TF TA TF TA TF TA TF TA TF TA TF TA
Rafal Dworakowski [1] 67 84 151 19.4 ± 1.1 23.4 ± 1.5 - - 4 11 5 4 11 2 3 5
Peter Wenaweser [2] 27 43 70 22.8 ± 13.0 26.1 ±14.3 6.3 ± 4.0 6.3 ± 5.5 3 4 0 1 - - 3 7
Cosmo Godino [3] 107 15 222 26.6 ± 16 32.2 ± 23 7 ± 4.9 8.3 ± 4.2 1 2 - - - - - -
He’ le ‘ ne Eltchaninoff [4] 161 71 232 - - - - 18 12 7 2 - 22 4
Johan M. Bosmans [5] 99 88 187 29 ± 15 33 ± 17 - - 5 2 2 7 - – 4 5
Matthias Thielmann [6] 15 24 39 12.7 ± 0.9 16.7 ± 4.4 15.1 ± 4.1 9.9 ± 7.5 2 5 - - -
Nawwar Al-Attar [7] 35 15 50 - - - - 3 4 - - - -
Mark D. Osten [8] 16 30 46 - - - 1 2 1 2 - - 1 3
Ronen Gurvitch [9] 169 101 270 - - - - 13 13 7 2 14 4 10 6
ZHAO Quan-ming [10] 28 20 48 20.6 ± 15.8 17.3 ± 16.1 - - 1 4 - - - -
Miriam Puls [11] 83 97 180 - - - - 4 2 - - - 37 18
KONSTANTINOS SPARGIAS [12] 59 32 91 26 ± 12 27 ± 15 - 1 2 5 4 - - - -
GERHARD SCHYMIK [13] 174 126 300 21.9 15.9 27.0 18.0 - - 13 5 - - - - - -
Martine Gilard [14] 2361 567 2928 21.2 ± 14.7 24.8 ± 17 14.5 ± 11.9 15.1 ±38.8 190 77 - - - - - -
Himbert [15] 51 24 75 25 ±13 28 ± 13 15 ± 7 18 ± 9 4 4 3 10 6 2 3 1
Rodés-Cabau [16] 168 177 345 - - 9.0 ±5.8 10.5 ± 6.9 16 20 5 3 - - 6 11
Malin Johansson [17] 10 30 40 25.6 ±15 23.5 ± 17 - - 2 2 2 1 - - 0 0
Martyn Thomasp [18] 463 575 1038 25.7 ± 14.5 29.1 ± 16.3 - - 29 59 11 16 106 27 31 42
ThierryLefe’ vre [19] 61 69 130 25.7 ± 11.5 33.8 ±14.4 11.3 ± 6.1 11.8 ± 6.8 5 3 2 1 17 3 1 2
John G. Webb [20] 113 55 168 - - - - 9 10 6 1 9 2 5 4
TAVI, transcatheter aortic valve implantation; TF, transfemoral; TA, transapical; STS, Society of Thoracic Surgeons.
*Mean±SD.
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Search strategy
We conducted a search on pub-med and web of knowledge
from 2002 through September 2012 using following terms:
aortic stenosis, aortic valve replacement, transcatheter
aortic valve implantation, TAVI, trans-artery, transfemoral,
trans-apical. Studies in the original research or review
articles were also considered.Selection criteria
Included studies must meet the following criteria: (a) the
studies must clearly describe the study design, country,
year of publication, end point. (b) Baseline characteristics
of patient in each study must be present (c) Follow-up
time is also needed.Data extraction
Two investigators independently browsed the studies by
title and abstract, finally making decision according to
full-text. Disagreements were discussed in a group. We
extracted the following information from each study:first author, year of publication, study population charac-
teristics, study size, study design, inclusion and exclusion
criteria, time of follow-up, and survival data.Data analysis
ORs and their 95% CIs were used to assess the difference
between two groups. The heterogeneity assumption was
assessed by an I-squared test. If the I2 < 50%, then we
thought the heterogeneity was not significant, and the
fixed effect model was used, otherwise, the random effect
model was used.
We first assessed possible sources of heterogeneity within
selected studies. For sensitivity analyses, we examined
whether excluding studies with substantial deviation
from Hardy –Weinberg equilibrium affected our pooled
estimates to find if our result is stable. Finally, we assessed
publication bias using funnel plots.
We used Cochrane Collaboration meta-analysis software,
Review Manager4.2 to perform data analysis. And data was
presented as mean ± SD, P value of 0.05 for any test or
model was considered to be statistically significant.
Further evaluation
(n=39)
Studies determined for meta-analysis
(n=20)
Studies excluded (n=204 ) :
Without control group: 109
Case report: 58
Review: 26
Studies excluded(n=19 ) 
No-full-text: 15
No English language: 4
Initial studies through pub-med 
and web of knowledge(n=232)
Figure 1 Process for selecting final studies.
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Characteristics of selected studies
A total of 20 studies met inclusion criterias and were
included in ouranalysis (4267 patients in TF group, 2242 in
TA group) [1-20]. No random clinical trial, one was a
retrospective study, others were prospective trials. Table 1
showed the characteristics of included studies. Figure 1
showed the process for selecting final studies.
Odds for 30-day clinical outcomes compared trans-
femoral approach with transapical approach in aortic valve
replacement.Figure 2 Compare 30-day mortality between transfemoral aortic valv
replacement for aortic stenosis.Postoperative 30-day mortality
The postoperative mortality was reported in 20 studies
[1-20] and meta-analysis of the data showed the pooled
postoperative mortality in TF was 7.5% (315/4267) as
compared with 11.3% (253/2242) in TA. As shown in
Figure 2, differences of postoperative mortality reach
statistical significance [0.63, 95%CI (0.52, 0.76)]. SAPIEN
bovine valve was used when patient receive TA and TF
procedure. In small studies, Core Valve were used when
patient receive TF procedure. As shown in Figure 3, we
performed meta-analysis with studies in which only
SAPIEN bovine valve was used and found that postopera-
tive mortality was 7.3% (116/1590) as compared with 11.0%
(157/1421) in TA.Post-operative stroke
Thirteen studies [1,2,4,5,8,9,12,15-20] reported the post-
operative stroke in patients ,meta-analysis of the resultant
data showed the pooled postoperative mortality in TF was
3.8% (56/1464) as compared with 4.0% (54/1380) in TA,
but did not reach statistical significance [0.88,95%CI
(0.60,1.29)], as shown in Figure 3. This finding was
consistent with previous study, where the overall 30-day
stroke was 3.3 ± 1.8%. There is evidence showed that valve
type may influence the incidence of postoperative stroke
[21]. We conducted a meta-analysis with studies where
only SAPIEN bovine valve was used ,and found postopera-
tive stroke in TF was 3.6% (51/1405) compared with 3.7%
(50/1348) in TA., but did not reach statistical significance
[0.90,95% CI(0.60,1.34)](as shown in Figure 4).e implantation versus transapical surgery aortic valve
Figure 3 Compare 30-day post-opertive stroke,heart block between transfemoral aortic valve implantation versus transapical surgery
aortic valve replacement for aortic stenosis.
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Differences of postoperative heart block were extracted
from 13 studies [1,2,4-5,8-9,11,15-20] and meta-analysis
of these data showed the pooled postoperative heart
block in TF was 8.5% (126/1488) as compared with 7.5%
(108/1445) in TA, but did not reach statistical significance
[1.18,95% CI(0.89,1.56)], as shown in Figure 3. There is
evidence that patients who undergo catheter valve
implantation with the CoreValve prosthesis are at higher
risk for post-operative heart block [5]. In 7 studies, both
Edwards SAPIEN bovine valve and Core Valve were used
when patient receive TF procedure. Then we conducted
meta-analysis with studies in which only SAPIEN bovine
valve was used. Data were extracted from 12 studies
and meta-analysis of these data showed the incidence
of postoperative heart block in TF was 6.3% (89/1405)
compared with 7.5% (90/1348) in TA., but did not reach
statistical significance [0.91,95% CI(0.67,1.26)](as shown in
Figure 4).Sensitivity analysis
Among the studies included in our meta-analysis, no
random clinical trials, one was a retrospective study and
others were prospective study. We first excluded the
retrospective study to find if study-design may influence
the result, then excluded studies with large ORs. Except
the reducing of I2 value, most pooled estimates were
similar and did not change materially. There is evidence
show that valve type may influence the incidence of
postoperative stroke and heart block [21]. We conducted
a meta-analysis with studies where only SAPIEN bovine
valve was used, and indicated that our results were
consistent.
Publication bias analysis
Funnel plot was used to assess the publication bias.
Figure 5 showed the funnel plot for all-cause 30-day
mortality. Although small studies with large standard
errors tended to scatter above the horizontal line for
Figure 4 Compare 30-day post-opertive mortality, stroke, heart block between transfemoral aortic valve implantation versus transapical
surgery aortic valve replacement for aortic stenosis with studies in which people received only SAPIEN bovine valve was used.
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were indicated (P = 0.230 for the Begg test; P = 0.171 for
the Egger test). And we found similar pooled estimate for
post-operative stroke and heart block with no publication
bias (P > 0.2 for the Begg test; P > 0.1 for the Egger test)
even after excluding the small studies in which all ORs
exceeded 3.0 and had wider CIs [1,2,5,15,16,18].Discussion
The Edwards-Sapien bioprosthesis has now been
approved for clinical use in the European Union and
preliminary guidance for its use has been published by
the National Institute of Clinical Excellence. But the
CoreValve has the advantage of a smaller introducer size
(18 Fr) for TF access in comparison with the 22/24 French
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This size allows for a larger use of TF implantation
in smaller arteries (6.0 mm). The TF approach was
used in 66% of procedures [4], the TA approach is an
alternative to TF for the Edwards SAPIEN device. Valve
implantation was performed using the first generation
Edwards SAPIEN prosthesis (Edwards Lifescience, Irvine,
CA) or the Medtronics COREVALVE (Med tronics Inc.,
Minneapolis, MN) in selected studies. Transfemoral use
of the Edwards SAPIEN prosthesis was the initial option
considered for all patients. In cases of inadequate arterial
anatomy (including small vessel diameter, severe calcifica-
tions, and/or severe arterial tortuosity), transapical use of
the Edwards SAPIEN prosthesis was considered. The
Medtronics COREVALVE was preferred for patients with a
large aortic annulus (diameter ranging from 23 to 27 mm),
in which case the first generation of Edwards SAPIEN
prosthesis was contraindicated.
With 4267 patients in TF group, 2242 in TA group
from 20 studies, our meta-analysis identified transfemoral
patients had a higher 30-day mortality of 7.5% compared
with 11.3% in the transapical patients. The reason for this
difference is unclear, but we believe that the difference in
mortality between two approaches is partially explained by
the different risk profiles of the patients and appropriate
clinical judgment strategies. Logistic EuroSCORE can be
helpful in identifying high risk patients. But it may not be
appropriate to extrapolate EuroSCORE algorithms based
on operated patients to this TAVI population, the majority
of which was deemed inoperable, and other clinical and
morphological variables (such as porcelain aorta, frailty,
planned multivalve surgery) are not captured by this score.Figure 5 Funnel plot test of the 11 studies included in our meta-analThe incidence of stroke at ≤ 30 days was relatively
low, 3.8% in the TF group and 4.0% in the TA group.
This may be related with careful patient selection,
device preparation, optimal device progression, and posi-
tioning, as well as adequate antiplatelet and anticoagulation
regimen. It has previously been suggested that the
stroke rate for the transfemoral group may be higher
than for the transapical group because of the passage
of the 22F or 24F sheath around the aortic arch [20].
But we found no significant difference [0.87, 95%CI
(0.59, 1.29)].
Incidence of the post-operative heart block comprising
sudden post-operative AV block or other cardiac
arrhythmia which need pace-maker implantation, is a
life-threatening complication. It is speculated that
conduction tissue injury during TAVI is induced by
mechanical pressure to the conduction system by the
prosthesis and the native valve calcium that remains in
situ. The risk of post-operative heart block in patients
with the Edwards SAPIEN valve prosthesis is lower than
that observed in patients with the CoreValve valve
prosthesis (6.3% for the TF and 7.5% TA approach).The
reasons are unclear but may relate to the fact that the
Edwards SAPIEN valve is shorter than the CoreValve device
and that there is continued pressure on the conduction
system in the septum by the self-expanding CoreValve.
Our study existed several limitations. First, publication
bias might have occurred because our study were wholly
based on studies published in English-language journals,
studies in other language and unpublished studies were
not included. Although the pooled estimate did not
change after we excluded the smallest studies with largeysis.
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TF advantages were overestimated because of publication
bias and patient selection criteria.
Some may also argue that the true effect of two
procedures on high risk patient can be quantified from
meta-analysis of studies with heterogeneous samples. We
dealt this concern primarily by using multiple sensitivity
analysis, all of the analysis produced consistent pooled
estimates, although false-positive finding are possible in
analysis because of small subgroups.
Conclusions
Our meta-analysis found that TF had the low incidence
of 30-day mortality compared with TA procedure (7.5%
versus 11.3%). The incidence of stroke at ≤ 30 days was
relatively low. Although the incidence of post-operative
heart block was high, but no differences were indicated.
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